Tarsus Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigat...
Latest News
11 days ago · globenewswire.com
Tarsus to Participate in Upcoming Investor ConferencesIRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:
13 days ago · marketbeat.com
Tarsus Pharmaceuticals Q3 Earnings Call HighlightsTarsus Pharmaceuticals NASDAQ: TARS reported record third-quarter sales for XDEMVY and raised its full-year revenue outlook, citing increased patient demand, deeper prescribing activity among eye care professionals and a growing contribution from retreatment prescriptions.
13 days ago · seekingalpha.com
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call TranscriptTarsus Pharmaceuticals, Inc. (TARS) Q3 2026 Earnings Call Transcript
13 days ago · zacks.com
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue EstimatesTarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $1.43. This compares to a loss of $0.3 per share a year ago.
13 days ago · globenewswire.com
Tarsus Reports Third Quarter 2026 Financial ResultsGenerated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-year Surpassed one million XDEMVY bottles dispensed and $1 billion in cumulative net product sales since launch Appointed Neera Clase as Chief Commercial Officer Management to host conference call today, November 3, 2026, at 1:30 p.m. PT / 4:30 p.m.
15 days ago · zacks.com
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
16 days ago · seekingalpha.com
My 'Eye' Is On Tarsus PharmaceuticalsTarsus Pharmaceuticals is well-positioned with Xdemvy's rapid commercial ramp and robust $2B peak sales potential. Recent acquisitions of IRX-101 and ALK-101 diversify the pipeline, adding both low-risk and high-reward late-stage assets. IRX-101's clinical data and market need suggest strong approval prospects and $600–900M peak sales, enhancing TARS' valuation case.
18 days ago · globenewswire.com
Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.
20 days ago · globenewswire.com
Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial OfficerIRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus' Interim Chief Commercial Officer since July 2026 and previously served as Senior Vice President of Market Access.
21 days ago · zacks.com
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to DeclineTarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TARS